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Recently, Sue et al. published an open-label study, aiming to
assess the efficacy of a 7-day first-line Helicobacter pylori (H.
pylori) eradication regimen with vonoprazan (VPZ), clari-
thromycin (CAM), and metronidazole (MNZ), in patients
with penicillin allergy [1]. In a letter to the editor, Kashani
and Abadi raised several criticisms of this article [2]. The
authors responded [3], but we want to focus on two not
redundant points.
Considering appropriate some considerations (already
reported by Sue et al.), especially those of the lack of controls
and of the small sample size, we do not agree with two points.
First, in the letter, it is reported that the factors affecting the
success rate of H. pylori therapy were not checked and,
among those, smoking habits and alcohol-drinking habits
were reported. About these factors, there is no universal
agreement in the literature [4, 5] and guidelines [6] on their
ability to predict a poor response.
Second, Kashani and Abadi reported the need to evaluate
CAM and MNZ resistance before deciding the appropriate
treatment [2]. This is correct [7]; however, it should be
highlighted that it is possible to obtain H. pylori eradication
with VPZ-based therapy in 70.2% of patients in whom
rabeprazole-based therapy (with the same antibiotics) has
failed [8]. Thus, VPZ-based treatment shows a relatively high
eradication rate against clarithromycin-resistant H. pylori. A
plausible explanation is that, since VPZ and CAM are
metabolized by CYP3A4, a combined treatment with these
three drugs can delay their clearance permitting a prolonged
and more potent effect. In addition, the strong and fast-
acting acid inhibitory effect of VPZ allowed the antibiotics to
eradicate H. pylori [9]. Nevertheless, the efficacy of VPZ has
not been reported for the combination of VPZ, CAM, and
MNZ. Regarding the comment of Kashani and Abadi on the
need to evaluate MNZ resistance by susceptibility tests, we
would highlight that this resistance, although highly preva-
lent, can be partly overcome and is of secondary importance.
Hence, the need to evaluate MNZ resistance patient-by-
patient could not be useful. It would be better to know in a spe-
cific populationMNZ andCAMresistance rates and apply the
recommendation of the more updated guidelines [6].
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